In additional to the traditional treatments, such as surgery, radiotherapy and chemotherapy, the target therapy like the inhibitors for epidermal growth factor receptor-tyrosine kinase (EGFR-TKIs) has been approved as a standard first-line therapy in NSCLC patients with sensitive EGFR mutations (Maemondo et al., 2010). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.